Table 2.
Top 30 different metabolites between groups of the training cohort.
| Class | Metabolite | Control (n = 36) |
AA (n = 28) |
CRC (n = 18) |
Post Hoc p-Value | ||
|---|---|---|---|---|---|---|---|
| Control vs. AA | Control vs. CRC | AA vs. CRC | |||||
| PC aa | PC aa C32:2 | 3.22 ± 0.96 | 2.60 ± 1.03 | 1.83 ± 0.76 | 0.031 | <0.001 | 0.028 |
| PC aa C32:3 | 0.29 ± 0.07 | 0.26 ± 0.07 | 0.20 ± 0.06 | 0.229 | <0.001 | 0.012 | |
| PC aa C34:3 | 11.08 ± 2.55 | 10.21 ± 3.29 | 7.54 ± 2.44 | 0.099 | <0.001 | 0.006 | |
| PC aa C34:4 | 1.40 ± 0.39 | 1.21 ± 0.52 | 0.74 ± 0.31 | 0.226 | <0.001 | 0.002 | |
| PC aa C36:3 | 87.51 ± 11.98 | 86.21 ± 16.29 | 70.58 ± 16.24 | 0.990 | 0.001 | 0.002 | |
| PC aa C36:6 | 0.59 ± 0.18 | 0.56 ± 0.27 | 0.31 ± 0.14 | 0.948 | <0.001 | <0.001 | |
| Total PC aa | 1039 ± 118 | 1055 ± 197 | 870 ± 147 | 0.969 | 0.001 | 0.001 | |
| PC ae | PC ae C38:0 | 1.40 ± 0.32 | 1.41 ± 0.50 | 0.92 ± 0.34 | 0.665 | <0.001 | 0.001 |
| PC ae C40:1 | 1.22 ± 0.18 | 1.17 ± 0.34 | 0.87 ± 0.27 | 0.159 | <0.001 | 0.003 | |
| PC aa, ae | PUFA PC | 940 ± 98 | 949 ± 167 | 788 ± 141 | 0.991 | 0.001 | 0.001 |
| Total PC | 1157 ± 129 | 1167 ± 210 | 970 ± 163 | 0.994 | 0.001 | 0.001 | |
| LysoPC | LysoPC a C16:0 | 128 ± 22 | 112 ± 22 | 97 ± 25 | 0.032 | 0.027 | 0.845 |
| LysoPC a C17:0 | 2.35 ± 0.48 | 1.85 ± 0.56 | 1.63 ± 0.60 | 0.001 | 0.007 | 0.980 | |
| LysoPC a C18:0 | 31 ± 6 | 26 ± 6 | 23 ± 8 | 0.012 | 0.024 | 0.939 | |
| LysoPC a C18:1 | 25 ± 5 | 21 ± 5 | 18 ± 6 | 0.034 | 0.033 | 0.876 | |
| LysoPC a C18:2 | 32 ± 9 | 27 ± 9 | 21 ± 9 | 0.041 | 0.001 | 0.167 | |
| LysoPC a C20:3 | 2.40 ± 0.61 | 2.06 ± 0.64 | 1.57 ± 0.5 | 0.129 | 0.019 | 0.476 | |
| LysoPC a C28:1 | 0.49 ± 0.10 | 0.43 ± 0.13 | 0.34 ± 0.10 | 0.233 | 0.003 | 0.090 | |
| Total lysoPC | 233 ± 38 | 201 ± 38 | 172 ± 46 | 0.007 | <0.001 | 0.056 | |
| SM | SM (OH)/SM (non-OH) | 0.16 ± 0.02 | 0.14 ± 0.02 | 0.14 ± 0.02 | 0.020 | <0.001 | 0.358 |
| AC | C2 | 6.49 ± 1.99 | 9.16 ± 3.50 | 8.86 ± 2.65 | <0.001 | 0.001 | 0.982 |
| C12:1 | 0.04 ± 0.056 | 0.08 ± 0.06 | 0.11 ± 0.07 | 0.004 | 0.001 | 0.215 | |
| C14:1 | 0.06 ± 0.02 | 0.09 ± 0.02 | 0.10 ± 0.04 | 0.002 | 0.007 | 0.920 | |
| C14:2 | 0.02 ± 0.01 | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.033 | 0.088 | 0.990 | |
| C18:1 | 0.11 ± 0.03 | 0.13 ± 0.03 | 0.16 ± 0.04 | 0.017 | <0.001 | 0.110 | |
| C2/C0 | 0.17 ± 0.04 | 0.24 ± 0.08 | 0.25 ± 0.08 | <0.001 | <0.001 | 0.514 | |
| (C2 + C3)/C0 | 0.18 ± 0.04 | 0.25 ± 0.08 | 0.26 ± 0.08 | <0.001 | <0.001 | 0.543 | |
| CPT-I-ratio | 0.0085 ± 0.002 | 0.0094 ± 0.002 | 0.012 ± 0.005 | 0.020 | <0.001 | 0.034 | |
| Total AC/C0 | 0.21 ± 0.05 | 0.30 ± 0.09 | 0.32 ± 0.09 | <0.001 | <0.001 | 0.322 | |
| Amine | Total DMA | 0.83 ± 0.12 | 0.89 ± 0.15 | 1.01 ± 0.16 | 0.307 | <0.001 | 0.007 |
AC, acylcarnitine; DMA, dimethylarginine; lysoPC, monoacyl-glycerophosphocholine; PC aa, diacyl-glycerophosphocholine; PC ae, alkyl-acyl-glycerophosphocholine; PUFA, poly-unsaturated fatty acid; SM, sphingomyelin; data are expressed in µM (except for ratios) as means ± standard deviation; p-values are assessed by ANOVA (Benjamini–Hochberg or Tamhane post hoc analysis) or Kruskal–Wallis test; p-values < 0.05 were considered to indicate statistical significance and are marked in bold.